BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26048772)

  • 1. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
    Pathak NM; Pathak V; Lynch AM; Irwin N; Gault VA; Flatt PR
    Mol Cell Endocrinol; 2015 Sep; 412():95-103. PubMed ID: 26048772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.
    Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR
    Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA; Lennox R; Flatt PR
    Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
    Lennox R; Porter DW; Flatt PR; Gault VA
    ChemMedChem; 2013 Apr; 8(4):595-602. PubMed ID: 23138973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
    Porter WD; Flatt PR; Hölscher C; Gault VA
    Int J Obes (Lond); 2013 May; 37(5):678-84. PubMed ID: 22665137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterisation of novel, enzymatically stable oxytocin analogues with beneficial antidiabetic effects in high fat fed mice.
    Mohan S; McCloskey AG; McKillop AM; Flatt PR; Irwin N; Moffett RC
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129811. PubMed ID: 33309687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
    Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
    Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
    Pathak V; Gault VA; Flatt PR; Irwin N
    Mol Cell Endocrinol; 2015 Feb; 401():120-9. PubMed ID: 25449420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
    Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
    Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet.
    Parlevliet ET; Heijboer AC; Schröder-van der Elst JP; Havekes LM; Romijn JA; Pijl H; Corssmit EP
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E142-7. PubMed ID: 17971509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.